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“the treatment horizon of ALK-positive NSCLC has evolved by the discovery of a number of TKIs
that target ALK gene rearrangement. The second generation ALK inhibitors have replaced
crizotinib which once was the first line agent in the treatment of ALK-positive NSCLC.”
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Lung cancer is the leading cause of cancer-related mortality, both worldwide and in the USA. Non-small-cell lung
cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. At the turn of 21st century, platinum
based cytotoxic chemotherapy was shown to offer modest survival benefit in metastatic NSCLC and remained
the only viable treatment option for a long time. Over the past decade, the therapeutic landscape of NSCLC has
expanded dramatically owing to the discovery of various driver mutations. Several molecularly targeted agents and
immune checkpoint inhibitors are now a part of the therapeutic armamentarium against this genetically complex
disease.
ALK gene encodes for a member of insulin receptor superfamily transmembrane receptor tyrosine kinase [1]. In
2007, chromosomal rearrangement involving ALK gene on chromosome 2 and EML4 gene on chromosome 5 was
first found to have potent transforming activity in NSCLC. Subsequently, preclinical studies suggested that this
fusion gene might be the driver mutation and potentially be a therapeutic target of NSCLC [2]. Approximately, 3–
7% of patients with NSCLC harbor the EML4–ALK gene rearrangement, which is mutually exclusive with EGFR
and KRAS mutations. ALK gene rearrangements are more common in younger patients with adenocarcinoma
histology and those with minimal or no smoking history. There are reports of ALK gene rearrangement in patients
with squamous cell and small-cell lung cancer; however, its clinical significance and potential as a therapeutic
target in these histologic subtypes remain unknown. The testing modalities for ALK rearrangement in NSCLC
include immunohistochemistry (IHC), FISH, and PCR; with the former two being the most commonly utilized
modalities. However, there is a variable rate of discordance in response to ALK inhibition in IHC-negative but
FISH-positive tumors, and therefore both IHC and FISH are currently recommended for ALK testing.
Crizotinib, originally developed as a c-MET inhibitor, is the first-in-class ALK inhibitor to show activity in ALK-
rearranged NSCLC. In addition, it is also active in ROS1-rearranged lung cancer. Crizotinib received accelerated
US FDA approval in 2011 based on a Phase I trial showing objective response rate (ORR) of 60% with a
median progression free survival (PFS) of 9.7 months and 12-month overall survival of 74.8% in patients with
ALK-rearranged NSCLC [3]. Subsequently, two randomized Phase III trials comparing crizotinib with standard
chemotherapy in second line and first-line settings confirmed significantly higher response rates and longer PFS
with crizotinib. No statistically significant overall survival difference was observed in either of these trials, largely
accounted for by significant crossover between the two arms [4,5].
Despite the striking results with this first ALK inhibitor, the success in personalized therapy was fraught with
several challenges. First, the majority of patients develop resistance to crizotinib within the first 12 months of
treatment. Several resistance mechanisms have been implicated and are broadly divided into two categories: ALK-
dominant, and ALK-nondominant [6]. ALK-dominant mechanisms predominantly comprise second mutations in
the ALK gene which include a gatekeeper mutation L1196M as well as other more recently reported mutations such
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as C1156Y, L1152R, 1151Tins, G1202R, S1206Y, F1174C, D1203N and G1269A [7]. ALK-nondominant mech-
anisms involve mutations in other oncogenes such as EGFR and KRAS, amplification of KIT, and transformation
to sarcomatoid carcinoma [8]. Second, CNS penetration of crizotinib is inadequate leading to disease progression
in CNS even in the presence of continued systemic response.
To overcome these challenges, a number of more potent and more selective ALK inhibitors have been developed.
Among these, second generation ALK inhibitors ceritinib, alectinib and brigatinib are currently approved by the
FDA. Ceritinib has shown activity in both, crizotinib naive and crizotinib resistant NSCLC, with improvement
in ORR and PFS leading to its approval as a second-line agent and subsequently first-line agent in patients with
advanced ALK-rearranged NSCLC [9–11]. Additionally, ceritinib has demonstrated superior CNS activity with
intracranial response rate of 57% compared with 22% with crizotinib [12].
Alectinib is ten-times more potent ALK-inhibitor than crizotinib and has also shown efficacy in both, crizotinib
naive and crizotinib resistant ALK-rearranged NSCLC, including the ones with gatekeeper mutation L1196M.
Early phase trials of alectinib demonstrated its excellent efficacy in previously untreated ALK-rearranged NSCLC
patients with ORR as high as 93.5% and more strikingly, no progression in the CNS in all enrolled patients [13,14].
Two randomized Phase III studies, J-ALEX and ALEX, comparing alectinib with crizotinib in previously untreated
patients with ALK-positive advanced NSCLC showed higher response rate, significantly prolonged event-free
survival, and lower rate of CNS progression with alectinib. In addition, alectinib was associated with lower rates
of grade 3–5 adverse events. These trials have led to approval of alectinib as a first line agent in the treatment of
ALK-positive NSCLC [15,16].
Alectinib offers substantial advantages over crizotinib in several aspects. First, it is active in ALK-positive NSCLC
resistant to crizotinib mediated by L1196M gatekeeper mutation, thereby conferring continued benefit in patients
who have disease progression while on crizotinib. Second, alectinib has significantly higher bioavailability in
CNS and can produce rapid and durable response in patients with brain metastases [17]. In addition, a recent
report suggested that in cases of disease progression in CNS after initial response to alectinib, dose intensification
from 600 to 900 mg twice daily can produce another durable response in CNS, particularly in patients with
leptomeningeal carcinomatosis [18]. Finally, alectinib has shown potent antitumor activity against RET-rearranged
NSCLC indicating its potential role in this subset of patients. In contrast to crizotinib, alectinib does not have any
appreciable activity against MET amplification or ROS1 rearrangement.
Brigatinib is another potent ALK inhibitor with an ability to overcome crizotinib resistance mutations [19].
Similar to alectinib, brigatinib yields high response rates, prolongs PFS, and has good CNS activity [20]. Brigatinib
is currently approved for the treatment of ALK-positive NSCLC following disease progression on crizotinib. In
contrast to alectinib, it is active against ALK resistance mutation G1202R, ROS1 and mutant EGFR including
T790M. The three second-generation ALK inhibitors have not been compared head-to-head, but they differ in
their efficacy and safety profiles as inferred from cross-trial comparisons. The efficacy appears to be lower with
ceritinib as compared with alectinib or brigatinib. Alectinib has the most robust CNS activity data and is active
against leptomeningeal disease as well [21]. With regards to safety profile, alectinib is best tolerated of the three ALK
TKIs and dose reductions are rarely necessary. Ceritinib is associated with GI side effects that require frequent dose
reductions. Finally, brigatinib is generally well tolerated; however, it is uniquely associated with pulmonary toxicity.
Therefore, it needs to be started at a lead-in dose of 90 mg daily for 7 days, and then escalated to standard dose of
180 mg daily to minimize the risk of pulmonary toxicity.
Several third generation ALK inhibitors, including ensartinib, entrectinib and lorlatinib, are being studied in
clinical trials [22,23]. Lorlatinib has obtained breakthrough therapy designation by the FDA and is currently available
for previously treated ALK- and ROS1-positive NSCLC patients through an expanded access protocol. It is active
in tumors harboring G1202R mutation in ALK that confers resistance to all first- and second-generation ALK
inhibitors.
As with other TKIs in cancer treatment, almost all the patients eventually develop resistance to ALK inhibitors.
The best strategy in that case is to obtain a biopsy of the growing lesion to analyze for the presence of resistance
mutations in ALK and utilize another ALK inhibitor that is known to have efficacy against identified resistance
mutation. There has been a case report of emergence of resistance mutations after disease progression on loralitnib
that resensitized the tumor to crizotinib [24]. This strategy allows sequential use of various ALK inhibitors with con-
tinued benefit for several years. However, at some point in time, all tumors develop ALK-independent mechanisms
of resistance, thereby requiring other treatment modalities.
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The efficacy of immune checkpoint inhibitors after disease progression on TKIs in ALK-translocated NSCLC
remains controversial. The majority of untreated ALK-translocated tumors demonstrate <50% PD-L1 expression.
Moreover, more than 70% of previously PD-L1-negative tumors remain PD-L1-negative, and approximately 30%
of previously PD-L1-positive tumors become negative after treatment with ALK inhibitors. Large randomized trials
comparing immune checkpoint inhibitors to second-line chemotherapy included very few ALK-positive patients,
however, the ORR and PFS with immune checkpoint inhibitors in this population were disappointing [25].
Therefore, current consensus is to utilize chemotherapy in patients with disease progression on ALK inhibitors.
A number of clinical trials evaluating combination of ALK inhibitors with other treatment modalities such as the
antiangiogenic agents and immune checkpoint inhibitors are currently ongoing. An interesting target in this realm
is heat shock protein HSP90, a molecular chaperone that plays a central role in regulating the correct folding,
stability and function of numerous proteins including EML4–ALK fusion protein [26]. Targeting the chaperone
function of HSP90 is therefore an alternative approach to direct kinase inhibition for therapeutic intervention in
ALK-driven NSCLC.
In summary, the treatment horizon of ALK-positive NSCLC has evolved by the discovery of a number of TKIs
that target ALK gene rearrangement. The second generation ALK inhibitors have replaced crizotinib which once was
the first line agent in the treatment of ALK-positive NSCLC. Two major advantages of newer ALK inhibitors over
crizotinib include superior bioavailability in the CNS thereby conferring high response rates in CNS disease (both
brain as well as leptomeningeal disease), and activity in the presence of certain resistance mutations. At present, it is
unclear if other ALK inhibitors will yield appreciable and durable responses in the second line setting after alectinib;
however, sequential treatment with ALK inhibitors selected based on the presence of resistance mutation can lead
to continued disease response for several years. Eventual development of ALK-independent resistance mechanisms
remains a challenge but the rapidly evolving field of personalized therapy will probably overcome this challenge in
the future.
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